STOCK TITAN

BioVie Inc - BIVI STOCK NEWS

Welcome to our dedicated news page for BioVie (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on BioVie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVie's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.65%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.19%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.42%
Tags
BioVie Inc

Nasdaq:BIVI

BIVI Rankings

BIVI Stock Data

26.80M
22.51M
43.25%
4.49%
2.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Carson City

About BIVI

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo